alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THIS  SCHEDULE  CONTAINS  SUMMARY  FINANCIAL   INFORMATION  EXTRACTED  FROM  THE
FINANCIAL  STATEMENTS CONTAINED IN THE COMPANY'S FORM 10-QSB AND IS QUALIFIED IN
ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>               JUL-31-1998
<PERIOD-START>                  JAN-01-1999
<PERIOD-END>                    APR-30-1999
<CASH>                                 405,068
<SECURITIES>                            0
<RECEIVABLES>                           1,150
<ALLOWANCES>                            0
<INVENTORY>                             0
<CURRENT-ASSETS>                        406,218
<PP&E>                                  0
<DEPRECIATION>                          0
<TOTAL-ASSETS>                          406,218
<CURRENT-LIABILITIES>                   0
<BONDS>                                 0
<PREFERRED-MANDATORY>                   0
<PREFERRED>                             0
<COMMON>                                11,100,000
<OTHER-SE>                              0
<TOTAL-LIABILITY-AND-EQUITY>            406,218
<SALES>                                 0
<TOTAL-REVENUES>                        4,499
<CGS>                                   0
<TOTAL-COSTS>                           7,043
<OTHER-EXPENSES>                        0
<LOSS-PROVISION>                        0
<INTEREST-EXPENSE>                      0
<INCOME-PRETAX>                         0
<INCOME-TAX>                            0
<INCOME-CONTINUING>                     0
<DISCONTINUED>                          0
<EXTRAORDINARY>                         0
<CHANGES>                               0
<NET-INCOME>                            (2,544)
<EPS-BASIC>                           0
<EPS-DILUTED>                           0





</TABLE>
```

[Congressional Bills 111th Congress]
[From the U.S. Government Publishing Office]
[S. 2669 Introduced in Senate (IS)]

111th CONGRESS
  1st Session
                                S. 2669

 To extend temporarily the suspension of duty on electrically operated 
                           pencil sharpeners.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                            November 2, 2009

   Mr. Burr introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
 To extend temporarily the suspension of duty on electrically operated 
                           pencil sharpeners.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. ELECTRICALLY OPERATED PENCIL SHARPENERS.

    (a) In General.--Heading 9902.22.82 of the Harmonized Tariff 
Schedule of the United States (relating to electrically operated pencil 
sharpeners) is amended by striking the date in the effective period 
column and inserting ``12/31/2011''.
    (b) Effective Date.--The amendment made by subsection (a) applies 
to goods entered, or withdrawn from warehouse for consumption, on or 
after the 15th day after the date of the enactment of this Act.
                                 <all>
```
NATIONAL INTERAGENCY FIRE CENTER

CASUAL PAYMENT CENTER

3833 S DEVELOPMENT AVE. MS 270, BOISE, ID 83705-5354

PHONE: 877-471-2262 FAX: 208-433-6405

EMAIL: CASUALPAY@BLM.GOV

STATE TAXES 

What You Need to Know While 

Working as a Casual! 

State Tax Procedures

Wages are required to be reported to the state in which you are hired. 

This is called your “Hired At State”. Therefore, a state tax record will 

be set up in your profile to withhold taxes for the state in which you are 

hired. If you submit a State Tax form indicating a different state than 

your Hired At State, taxes will be deducted for both states.

Example 1: You are hired out of an Arizona office, and then you work/

live in Utah:

• Taxes will be deducted for Arizona. 

• Taxes will not be deducted for Utah unless you submit a form 

for Utah state taxes. Always indicate “Utah State Taxes Only” 

at the top of the form (or appropriate residence state).

The only time you can opt to remove your Hired At State from your 

profile is when there is a reciprocal agreement in place. 

Example 2: You are hired out of a Montana office, and then you work/

live in North Dakota:

• A tax record for Montana will be set up in your profile; 

however, because these two states have a reciprocal 

agreement, you may send us a form to remove Montana and 

add North Dakota if you would like. 

You should always discuss withholding and exemption options 

with your tax advisor.

What am I responsible for?

• It is your responsibility to make sure your profile is correct and upto-date!

• If unsure of the State(s) you have elected to withhold tax, 

contact our office. Tax designations are also indicated on your 

Wage and Earning Statements. 

• You may email forms to our office to update your profile. Forms 

and a list of state reciprocal agreements can be found on our 

website at: https://www.nifc.gov/programs/casual-payment-center

TAXES WITHHELD 

FROM THE WRONG 

STATE?

• If you notice before the 

end of the year that 

taxes were withheld from 

an incorrect state, you 

may contact us to submit 

a tax correction form. 

• If you notice after the end 

of the year that taxes 

were withheld from an incorrect state, taxes cannot be reversed. At that 

point you should contact 

a tax professional about 

filing tax returns for both 

states.
```

[Congressional Bills 111th Congress]
[From the U.S. Government Publishing Office]
[S. 2693 Introduced in Senate (IS)]

111th CONGRESS
  1st Session
                                S. 2693

          To suspend temporarily the duty on Methyl acrylate.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                            November 2, 2009

   Mr. Burr introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
          To suspend temporarily the duty on Methyl acrylate.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. METHYL ACRYLATE.

    (a) In General.--Subchapter II of chapter 99 of the Harmonized 
Tariff Schedule of the United States is amended by inserting in 
numerical sequence the following new heading:

``     9902.01.00      Methyl acrylate     Free         No change        No change        On or before 12/  ''.
                        (CAS No. 96-33-3)                                                  31/2011.......
                        (provided for in
                        subheading
                        2916.12.50)......

    (b) Effective Date.--The amendment made by subsection (a) applies 
to goods entered, or withdrawn from warehouse for consumption, on or 
after the 15th day after the date of the enactment of this Act.
                                 <all>
```
-  Home 
        -  Research & Funding 
        -  Research Programs & Contacts 
        -  Translational Research 
        -  Clinical Development 

Translational Research
-  Disease Biology 
-  Target Identification 
-  Assay Development 
-  Screening 
-  Hit to Lead 
-  Lead Optimization 
-  Pre-Clinical Development 
-  Clinical Development 

# Translational Research: Clinical Development

Clinical evaluation of novel pre-therapeutics involves a highly regulated process by which the agent is carefully testedin clinical populations. The precise design of these studies varies by the nature of the agent, and in the case ofrepurposed compounds or naturally occurring biologics may involve existing human safety data. Clinical evaluationof compounds is a continuing process involving larger clinical trials through post-marketing monitoring.

          -  DiseaseBiology**Previous 
          -  UnvalidatedTargetTarget ID**PutativeTargetsPreviousNext 
          -  NominatedTargetAssay Development**ScreenableAssaysPreviousNext 
          -  Target AssayScreening**Hits andStarting PointsPreviousNext 
          -  HitHit to Lead**Lead SeriesPreviousNext 
          -  LeadCompoundLeadOptimization**PotentialTherapeuticLeadsPreviousNext 
          -  Pre‐clinicalCandidatePre‐clinicalDevelopment**ClinicalTherapeuticCandidatePreviousNext 
          -  ClinicalCandidateClinicalDevelopment**Clinical Proofof ConceptPreviousNext 
          -  Licensing andCommercializa-tion PartnersMarket-readyTherapeutics 

## NIH Funding Opportunities

- PA-20-185 , NIH Research Project Grant
- RFA-NS-24-019 , HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)

- Potential opportunities include ancillary studies to ongoing clinical studies, exploratory/developmental grants, and investigator-initiated multi-center clinical studies.

## Related Resources

- NIDDK Central Repository
- NCATS TRND
- Academic Drug Discovery Consortium
- NIDDK Small Business Programs

## Contacts

For more information on NIDDK funding opportunities to support clinical development and testing of new therapeutics, please visit the NIDDK Human Subjects Research page.
EXHIBIT 23.1

            CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


We consent to the incorporation by reference in the Registration Statements on
Form S-8 (Registration No. 33-71822) and Form F-3 (No. 333-112136 , 33-98599 and
333-121611) of our report dated February 17, 2005, with respect to the
consolidated financial statements of LanOptics Ltd., included in this Annual
Report on Form 20-F for the year ended December 31, 2004.



                                                        Yours Truly,


MARCH 31, 2005                                   KOST FORER GABBAY & KASIERER
Tel-Aviv, Israel                               A Member of Ernst & Young Global
II 

111TH CONGRESS 

1ST SESSION S. 2711 

To extend the temporary suspension of duty on dimethyl malonate. 

IN THE SENATE OF THE UNITED STATES 

NOVEMBER 2, 2009 

Mr. LAUTENBERG introduced the following bill; which was read twice and 

referred to the Committee on Finance 

A BILL 

To extend the temporary suspension of duty on dimethyl 

malonate. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. DIMETHYL MALONATE. 

4 (a) IN GENERAL.—Heading 9902.23.49 of the Har5 monized Tariff Schedule of the United States (relating to 

6 dimethyl malonate) is amended by striking ‘‘12/31/2009’’ 

7 and inserting ‘‘12/31/2011’’. 

8 (b) EFFECTIVE DATE.—The amendment made by 

9 subsection (a) applies with respect to goods entered, or 


smartinez on DSKB9S0YB1PROD with BILLS
2 

•S 2711 IS

1 withdrawn from warehouse for consumption, on or after 

2 the 15th day after the date of the enactment of this Act. 

Æ 


smartinez on DSKB9S0YB1PROD with BILLS
```

[Congressional Bills 111th Congress]
[From the U.S. Government Publishing Office]
[S. 2594 Introduced in Senate (IS)]

111th CONGRESS
  1st Session
                                S. 2594

      To extend temporarily the suspension of duty on mixtures or 
     coprecipitates of lanthanum phosphate, cerium-doped lanthanum 
          phosphate, cerium phosphate, and terbium phosphate.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                            October 30, 2009

Mrs. Hutchison introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
      To extend temporarily the suspension of duty on mixtures or 
     coprecipitates of lanthanum phosphate, cerium-doped lanthanum 
          phosphate, cerium phosphate, and terbium phosphate.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. MIXTURES OR COPRECIPITATES OF LANTHANUM PHOSPHATE, CERIUM-
              DOPED LANTHANUM PHOSPHATE, CERIUM PHOSPHATE, AND TERBIUM 
              PHOSPHATE.

    (a) In General.--Heading 9902.23.05 of the Harmonized Tariff 
Schedule of the United States (relating to mixtures or coprecipitates 
of lanthanum phosphate, cerium-doped lanthanum phosphate, cerium 
phosphate, and terbium phosphate) is amended by striking the date in 
the effective column period and inserting ``12/31/2011''.
    (b) Effective Date.--The amendment made by subsection (a) applies 
to goods entered, or withdrawn from warehouse for consumption, on or 
after the 15th day after the date of the enactment of this Act.
                                 <all>
```
**Exhibit 31.1****Sarbanes-Oxley Section 302 Certification**I, Stephen J. Hansbrough, certify that:1. I have reviewed this quarterly report on Form 10-Q of HearUSA, Inc.;2. Based on my knowledge, this report does not contain any untrue statement of a material fact oromit to state a material fact necessary to make the statements made, in light of the circumstancesunder which such statements were made, not misleading with respect to the period covered by thisreport;3. Based on my knowledge, the financial statements, and other financial information included inthis l report, fairly present in all material respects the financial condition, results ofoperations and cash flows of the registrant as of, and for, the periods presented in this report;4. The registrant’s other certifying officer and I are responsible for establishing and maintainingdisclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) forthe registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosurecontrols and procedures to be designed under our supervision, to ensure that materialinformation relating to the registrant, including its consolidated subsidiaries, ismade known to us by others within those entities, particularly during the period inwhich this report is being prepared;  b) Evaluated the effectiveness of the registrant’s disclosure controls andprocedures and presented in this report our conclusions about the effectiveness of thedisclosure controls and procedures, as of the end of the period covered by this reportbased on such evaluations; and  c) Disclosed in this report any change in the registrant’s internal control overfinancial reporting that occurred during the registrant’s most recent fiscal quarter(the registrant’s fourth fiscal quarter in the case of an annual report) that hasmaterially affected, or is reasonably likely to materially affect, the registrant’sinternal control over financial reporting; and5. The registrant’s other certifying officer and I have disclosed, based on our most recentevaluation of internal control over financial reporting, to the registrant’s auditors and the auditcommittee of registrant’s board of directors (or persons performing the equivalent function): a) All significant deficiencies and material weaknesses in the design or operationof internal control over financial reporting which are reasonably likely to adverselyaffect the registrant’s ability to record, process, summarize and report financialinformation; and  b) Any fraud, whether or not material, that involves management or otheremployees who have a significant role in the registrant’s internal control overfinancial reporting.Date: November 9, 2005   /s/ Stephen J. Hansbrough   Stephen J. Hansbrough  Chief Executive Officer
Exhibit No. 32.1


Alliance Health, Inc.


File No. 33-17387


Form 10-Q


Quarter ended March 31, 2010





Certification Pursuant to 18 U.S.C. Section 1350, as Adopted


Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002





In connection with the Quarterly Report of Alliance Health, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sarkis J. Kechejian, Chief Executive and Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:




(1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and





(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.







Dated: May 12, 2010
/s/ Sarkis J. Kechejian, M. D.Sarkis J. Kechejian, M. D.Chief Executive Officerand Chief Financial Officer


A signed original of this written statement required by Section 906 has been provided to Alliance Health, Inc. and will be retained by Alliance Health, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
II 

111TH CONGRESS 

1ST SESSION S. 2641 

To extend the temporary suspension of duty on N,N-Hexane-1,6-diylbis(3- 

(3,5-di-tert-butyl-4-hydroxyphenylpropionamide)). 

IN THE SENATE OF THE UNITED STATES 

NOVEMBER 2, 2009 

Mr. SESSIONS introduced the following bill; which was read twice and referred 

to the Committee on Finance 

A BILL 

To extend the temporary suspension of duty on N,N-Hexane1,6-diylbis(3-(3,5-di-tert-butyl-4- 

hydroxyphenylpropionamide)). 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. N,N-HEXANE-1,6-DIYLBIS(3-(3,5-DI-TERT-BUTYL4 4-HYDROXYPHENYLPROPIONAMIDE)). 

5 (a) IN GENERAL.—Heading 9902.24.23 of the Har6 monized Tariff Schedule of the United States (relating to 

7 N,N-Hexane-1,6-diylbis(3-(3,5-di-tert-butyl-4- 

8 hydroxyphenylpropionamide))) is amended by striking 

9 ‘‘12/31/2009’’ and inserting ‘‘12/31/2011’’. 


tjames on DSKG8SOYB1PROD with BILLS
2 

•S 2641 IS

1 (b) EFFECTIVE DATE.—The amendment made by 

2 subsection (a) applies to goods entered, or withdrawn from 

3 warehouse for consumption, on or after the 15th day after 

4 the date of the enactment of this Act. 

Æ 


tjames on DSKG8SOYB1PROD with BILLS
INTERAGENCY WILDLAND FIRE HIRING OFFICIAL RECRUITMENT CHECKLIST

Submit this form with the recruitment package when requesting advertisement of a fire position. In addition to this

form, the recruitment package may include associated position description, job analysis, questionnaire, rating plan, and

other position specific information.

A. Position Information

    11/05/2010

Position Number

Position Title (classified), Series and Grade

Unit /Organization Name

Position Description Number (i.e. DOI000)

Duty Station

Immediate Supervisor’s Name, Position

Supervisor Phone Number

B. Interagency Fire Program Management (IFPM) Position (http://www.ifpm.nifc.gov)

If position is recruited as an IFPM position, please indicate by check mark the correct position.  If non‐IFPM, skip to

Section C:

√  IFPM Position Position Complexity  (√ where applicable)

Low Mod High

National Fire Program Manager (NFPM)

Geographic Fire Program Manager (GFPM)

Unit Fire Program Manager (UFPM)

Prescribed Fire & Fuels Specialist (PFFS)

Wildland Fire Operations Specialist (WFOS)

Supervisory Engine Operator (SEOP)

Engine Module Supervisor (EMLS)

Interagency Hotshot Crew Superintendent (IHCS)

Helicopter Manager (HEMG)

Senior Firefighter (SFF)

Center Manager (CMGR)

Lead Dispatcher/Assistant Center Manager (ACMG)

Initial Attack Dispatcher (IADP)

IFPM NWCG Requirements

Primary Core Requirement(s)

Secondary Core Requirement(s)

Additional Required Training

C. Non‐IFPM  Wildland  Fire Positions  

Some non‐IFPM fire positions require selective factors (NWCG Qualifications, etc.).  List below any and cite reference

document (i.e. Red Book, Blue Book, IHOG, etc.).  Attach a brief justification to support use of the selective factor.

Selective Factor

Selective Factor

Selective Factor

D. Secondary (Administrative) FF Retirement Coverage?     Yes          No      (Circle One)     

(If yes, add selective factor of 90 days previous wildland fire experience to the announcement.)

Hiring Official Signature: _________________________________    Date: __________________
[Federal Register Volume 74, Number 205 (Monday, October 26, 2009)]
[Notices]
[Page 55069]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-25641]


=======================================================================
-----------------------------------------------------------------------

NATIONAL FOUNDATION ON THE ARTS AND THE HUMANITIES


National Endowment for the Arts; President's Committee on the 
Arts and the Humanities: Meeting <greek-i>65

    Pursuant to Section 10(a)(2) of the Federal Advisory Committee Act 
(Pub. L. 92-463), as amended, notice is hereby given that a meeting of 
the President's Committee on the Arts and the Humanities (PCAH) will be 
held on November 4, 2009, from 9 to 11:30 a.m. The meeting will be held 
in the Pierce Room, The Willard Intercontinental, 1401 Pennsylvania 
Avenue, NW., Washington, DC 20004.
    The Committee meeting will begin with welcome, introductions, and 
announcements. Updates and discussion on recent programs and activities 
will follow. The meeting will also include a review of PCAH ongoing 
programming for youth arts and humanities learning, preservation and 
conservation, special events, and international cultural projects. The 
meeting will adjourn after discussion of other business, as necessary, 
and closing remarks.
    The President's Committee on the Arts and the Humanities was 
created by Executive Order in 1982, which currently states that the 
``Committee shall advise, provide recommendations to, and assist the 
President, the National Endowment for the Arts, the National Endowment 
for the Humanities, and the Institute of Museum and Library Services on 
matters relating to the arts and the humanities.''
    Any interested persons may attend as observers, on a space 
available basis, but seating is limited. Therefore, for this meeting, 
individuals wishing to attend are advised to contact Jennifer Schmidt 
of the President's Committee seven (7) days in advance of the meeting 
at (202) 682-5560 or write to the Committee at 1100 Pennsylvania 
Avenue, NW., Suite 526, Washington, DC 20506. Further information with 
reference to this meeting can also be obtained from Ms. Schmidt.
    If you need special accommodations due to a disability, please 
contact the Office of AccessAbility, National Endowment for the Arts, 
1100 Pennsylvania Avenue, NW., Suite 724, Washington, DC 20506, (202) 
682-5532, TDY-TDD (202) 682-5496, at least seven (7) days prior to the 
meeting.

    Dated: October 21, 2009.
Kathy Plowitz-Worden,
Panel Coordinator, Office of Guidelines and Panel Operations.
[FR Doc. E9-25641 Filed 10-23-09; 8:45 am]
BILLING CODE P
THE THIRTEENTH COURT OF APPEALS

13-20-00221-CV

Roel Garcia

v.

Javier Prieto Gonzalez

On Appeal from the

398th District Court of Hidalgo County, Texas

Trial Court Cause No. C-7372-14-I

JUDGMENT

THE THIRTEENTH COURT OF APPEALS, having considered this cause on 

appeal, concludes the appeal should be dismissed. The Court orders the appeal 

DISMISSED in accordance with its opinion. Costs of the appeal are adjudged against 

appellant.

We further order this decision certified below for observance.

November 18, 2021